Neurogene (NASDAQ:NGNE) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Neurogene (NASDAQ:NGNE) posted its quarterly earnings results on Tuesday. The company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.42) by ($0.11), FiscalAI reports.

Neurogene Trading Down 5.5%

NGNE opened at $34.54 on Tuesday. The firm’s 50 day simple moving average is $33.34 and its two-hundred day simple moving average is $26.46. The company has a market capitalization of $545.73 million, a PE ratio of -7.49 and a beta of 1.70. Neurogene has a 1-year low of $15.93 and a 1-year high of $43.66.

Wall Street Analyst Weigh In

Several brokerages have issued reports on NGNE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. Rodman & Renshaw initiated coverage on shares of Neurogene in a report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price target on the stock. Guggenheim started coverage on shares of Neurogene in a research report on Tuesday, April 28th. They set a “buy” rating and a $69.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, June 9th. Finally, UBS Group set a $70.00 price objective on Neurogene in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $84.83.

Insider Activity

In other news, CFO Christine Mikail Cvijic sold 4,200 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total transaction of $151,746.00. Following the completion of the sale, the chief financial officer owned 84,040 shares of the company’s stock, valued at $3,036,365.20. The trade was a 4.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 9,600 shares of company stock worth $339,932. Insiders own 11.68% of the company’s stock.

Hedge Funds Weigh In On Neurogene

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. Daiwa Securities Group Inc. bought a new position in shares of Neurogene in the fourth quarter worth about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the period. Bridgeway Capital Management LLC purchased a new position in shares of Neurogene during the 3rd quarter valued at about $187,000. Finally, Wells Fargo & Company MN lifted its position in shares of Neurogene by 45.2% during the 4th quarter. Wells Fargo & Company MN now owns 11,037 shares of the company’s stock valued at $227,000 after buying an additional 3,438 shares in the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.